Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky lessened its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 81.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,138 shares of the specialty pharmaceutical company's stock after selling 87,250 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Jazz Pharmaceuticals were worth $2,243,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. LSV Asset Management raised its holdings in shares of Jazz Pharmaceuticals by 4.2% in the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company's stock worth $264,750,000 after buying an additional 99,705 shares during the last quarter. Pacer Advisors Inc. increased its position in shares of Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock valued at $233,892,000 after acquiring an additional 278,465 shares during the period. Baupost Group LLC MA raised its stake in Jazz Pharmaceuticals by 52.8% in the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock worth $136,000,000 after acquiring an additional 440,552 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Jazz Pharmaceuticals by 48.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company's stock worth $130,447,000 after acquiring an additional 398,549 shares during the period. Finally, Thompson Siegel & Walmsley LLC grew its stake in Jazz Pharmaceuticals by 8.3% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company's stock valued at $87,035,000 after purchasing an additional 59,685 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,753 shares of company stock worth $816,289 in the last quarter. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Price Performance

JAZZ stock traded up $2.16 during mid-day trading on Monday, reaching $125.20. 766,954 shares of the company's stock were exchanged, compared to its average volume of 668,194. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The stock's 50 day moving average is $117.39 and its 200 day moving average is $112.22. The company has a market cap of $7.57 billion, a price-to-earnings ratio of 17.63, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57.

Analysts Set New Price Targets

JAZZ has been the subject of several research analyst reports. Needham & Company LLC restated a "buy" rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a research report on Monday, August 19th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. TD Cowen reduced their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a report on Thursday, November 7th. Finally, Piper Sandler restated an "overweight" rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.